Chemotherapy in Biological Technology

Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

... of cancer stem cells found in tumors compared to chemotherapy alone. In addition, we demonstrated that ... with approved chemotherapeutic agents versus chemotherapy alone on the frequency of cancer stem cells in ... colon and breast tumors. Notably, treatment with chemotherapy alone was demonstrated to increase the ratio of ...

Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress

... adjunct to standard measures in helping determine chemotherapy benefit for early-stage breast cancer patients. ... Oncotype DX breast cancer test was used to guide chemotherapy treatment indicating that breast cancer in men ... which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage ...

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

... be used prophylactically with all radiation or chemotherapy regimens that have the potential to lead to oral ... treatments. Up to 40% of all patients receiving chemotherapy and/or radiotherapy develop moderate to severe ... used prophylactically for patients undergoing chemotherapy and radiation therapy, is estimated to be in ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... Therapy I-3 Radiation Therapy I-4 chemotherapy I-4 Surgical Procedures I-4 Other ... (WPRT) II-40 New Radiation Devices II-40 chemotherapy II-40 Risks Associated with chemotherapy II-41 Surgical Procedures for Prostate Cancer ...

Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer

... Adjunct to Standard Measures in Helping Determine chemotherapy Benefit - GENEVA, and REDWOOD CITY, Calif., ... adjunct to standard measures in helping determine chemotherapy benefit for early-stage breast cancer patients. ... to the guidelines, the threshold for recommending chemotherapy in treating estrogen receptor (ER) positive, ...

Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

... with 50% of patients having failed three prior chemotherapy treatments. More than 70% of the patients on both ... superior clinical benefits over standard of care chemotherapy treatment. "We are pleased that the PIX 301 ... it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... similar to the Reddy BK et al study although the chemotherapy dose intensity had slight differences in favor of ... irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl ... trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage ...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

... given every 3 weeks in combination with standard chemotherapy docetaxel (Taxotere(R)) in relapsed MBC patients who had a median of three prior chemotherapy regimens (n=22 assessable for safety and n=19 ... indicate that adding adecatumumab to standard chemotherapy is feasible," said Carsten Reinhardt, M.D., ...

Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting

... Level 2, West Hall D1 The 70-gene profile and chemotherapy benefit in 1,600 breast cancer patients ... West Hall C Cost effectiveness of targeting chemotherapy with the 70-gene prognostic signature in ... Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. ...

Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial

... of Craig Philips, President of CTI, "The standard chemotherapy regimen (CHOP) for this disease exposes patients ... (CRu) compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02) with no patients in the ...

Lilly Set to Unveil More Than 50 Studies at ASCO 2009

... by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced ... alone or in combination with cisplatin, another chemotherapy drug, are low blood cell counts (red blood cells, ... cancer after they have received another type of chemotherapy called an anthracycline, unless their medical ...

Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results

... treated with REOLYSIN in combination with chemotherapy or radiation, paving the way for our pivotal ... include those who have not received chemotherapy treatment for their metastatic or ... the use of REOLYSIN(R) in combination with chemotherapy for various cancer indications. These ...

Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer

... to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that ... than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor ... to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple ...

Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer

... product candidate, is a new generation platinum chemotherapy agent in clinical development to treat multiple ... to overcome platinum resistance associated with chemotherapy in solid tumors. Phase 1 CRC Study Design ... to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that ...

Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models

... - - University of Pennsylvania data on chemotherapy resistance patterns in neuroblastoma cell lines, ... used together with tyrosine kinase inhibitors or chemotherapy in vitro in those cell lines. "AT-406 is ... (BH) family proteins in the development of chemotherapy resistance in neuroblastoma (Abstract # 3269). ...

Groundbreaking Research Begins for Pancreatic and Lung Cancers

... There is also interest in the molecular basis of chemotherapy resistance. Some tumors respond very well to chemotherapy while others acquire resistance. By comparing the ... patterns in tumors that have become resistant to chemotherapy with patterns of these same tumors prior to ...

Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer

... agent (VDA) NPI-2358 in combination with standard chemotherapy (docetaxel) in patients with non-small cell lung ... with NSCLC who previously failed at least one chemotherapy regimen. Overall survival will be the primary ... a treatment that improves the outcomes of current chemotherapy regimens. Recent data suggest that VDAs could ...

Agendia Presents Data Supporting MammaPrint's Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference

... 70-gene MammaPrint Signature Is Predictive for chemotherapy Benefit in Early Breast Cancer M Knauer, ... Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In ... a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and ...

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

... in combination with docetaxel as second-line chemotherapy in patients with CRPC. - In the ... or docetaxel retreatment as second-line chemotherapy as compared to reported survival durations ... either docetaxel or mitoxantrone as second-line chemotherapy was approximately 10 months. A ...

Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

... Activity Across Doses and Endpoints in both chemotherapy Naive and Post-Chemotherapy Patients - - ... and 43 percent having also failed one or more chemotherapy regimens. Efficacy endpoints in the study ... favorable counts at week 12 (89 percent of chemotherapy naive patients and 100 percent of ...

Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer

... candidate, is a new generation platinum-based chemotherapy agent with the potential to become a platform ... to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date indicate that ... than is commonly observed with other platinum chemotherapy drugs. It is being studied in multiple cancer ...

Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer

... ability for neoadjuvant and adjuvant chemotherapy regimens," commented Dr. Bernhard Sixt, Ph.D., ... Only early metastasis risk can be reduced by chemotherapy as shown by the Early Breast Cancer ... series of 167 patients who received neoadjuvant chemotherapy for stage II or III breast cancer was analyzed ...

OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer

... trial of OGX-011 in combination with first-line chemotherapy for the treatment of advanced non-small cell lung ... patients who had received OGX-011 with first-line chemotherapy were alive. OncoGenex has previously reported a ... regimen plus gemcitabine as first-line chemotherapy for advanced NSCLC reported median survivals of 8 ...

Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

... candidate, is a new generation platinum-based chemotherapy agent with the potential to become a platform ... to overcome platinum resistance associated with chemotherapy in solid tumors. It has an improved safety ... than is commonly observed with other platinum chemotherapy drugs. It is being studied in multiple cancer ...

Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay

... alone and the magnitude of treatment benefit with chemotherapy following surgery. Results from the study are ... the likelihood of recurrence or magnitude of chemotherapy benefit for individual patients. "There is a ... of the Treatment Score with the magnitude of chemotherapy benefit in patients treated with adjuvant 5FU/LV ...

Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project

... whereas two technicians are needed when chemotherapy IVs are manually prepared in a BSC, one to make ... production of around 27,000 patient-specific chemotherapy IV doses. It is composed of the ... prepares approximately 80,000 patient-specific chemotherapy IV doses annually. About General Hospital ...

Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting

... sufficient data with Vectibix in combination with chemotherapy to conclude that KRAS is a valid predictive ... in wild-type KRAS tumors in combination with chemotherapy and to determine the clinical utility of KRAS ... oxaliplatin- and irinotecan-containing chemotherapy regimens. The effectiveness of Vectibix for the ...

Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias

... hematological remission following intense chemotherapy regimens, but retain ALL cancer cells in their ... confirmed that ALL patients with MRD following chemotherapy have a significantly worse prognosis than ... therapy after prior incomplete response to chemotherapy or even targeted therapy." "The level of ...

Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium

... its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage ... in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of ... of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast ...

Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting

... and efficacy of AEG35156 in combination with chemotherapy in AML patients in first relapse after a short ... Oligonucleotide (AEG35156) in Combination with chemotherapy in Patients with Relapsed/Refractory AML". ... Oligonucleotide (AEG35156) in Combination with chemotherapy in Patients with Relapsed/Refractory AML ...

Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated

... result influenced recommendations concerning chemotherapy in 37 patients (44 percent). Thirty- three ... who would have received a recommendation against chemotherapy based on the 2007 NCCN guidelines were placed in ... that Oncotype DX optimizes the use of chemotherapy to ensure those women ...

Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents

... to determine on how AHCC interacts with select chemotherapy agents. As most chemotherapy agents undergo ... pathway for metabolism of the most commonly used chemotherapy agents. "Research shows that AHCC benefits ... that AHCC is safe to administer with most chemotherapy agents." In addition to this study, research ...

Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer

... product candidate, is a new generation platinum chemotherapy agent with the potential to become a platform ... to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple ... than is commonly observed with other platinum chemotherapy drugs. In addition to the Phase 2 clinical ...

Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer

... product candidate, is a new generation platinum chemotherapy agent with the potential to become a platform ... to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple ... than is commonly observed with other platinum chemotherapy drugs. In addition to the ongoing Phase 2 ...

High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma

... transplant. High-dose myeloablative chemotherapy is an effective therapy for NHL but because it is ... old. In this study, three cycles of conventional chemotherapy were given followed by high dose chemotherapy with a stem cell rescue and then followed by ...

OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011

... "Our data combining OGX-011 with second line chemotherapy in patients with HRPC has shown potential ... to the 22-35% of patients receiving first-line chemotherapy who reported a reduction in pain in the primary ... treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin ...

33rd ESMO Congress in Stockholm, 12-16 September 2008

... Late-breaking data: extended, escalated dose chemotherapy shows no survival benefit in advanced disease ... America. Breast Cancer Adding docetaxel to chemotherapy regimen improves survival in early breast ... 16 September 2008, 10:00 CEST) A new form of chemotherapy that destroys new blood vessels that grow around ...

Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today

... OGX-011 in combination with second-line chemotherapy in patients with hormone refractory prostate ... including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has ... of 2008, and for OGX-427 in combination with chemotherapy in the first half of 2009. Phase 2 clinical ...

Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study

... Study Receiving Combination of Bavituximab Plus chemotherapy Achieved Objective Tumor Response or Stable ... bavituximab in combination with chemotherapy in patients with advanced cancer were presented ... showed that the safety profile of bavituximab and chemotherapy appeared consistent with chemotherapy alone and ...

Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy

... Genomic Grade Could Spare Tens of Thousands chemotherapy Treatments per Year ASCO Annual ... treat high-grade "grade 3" breast carcinoma with chemotherapy because they are chemosensitive and will often ... "grade 1" tumors should not be treated with chemotherapy because they have a good prognosis and are ...